Synchrony Medical Secures $5M Funding for LibAirty System Expansion

JERSEY CITY, New Jersey & OR YEHUDA, Israel—Synchrony Medical, a respiratory care technology company and creator of the FDA-cleared LibAirty Airway Clearance System, announced it has closed an oversubscribed $5 million funding round. The investment, led by Edge Medical Ventures with participation from the New Jersey Economic Development Authority (NJEDA), Broadfin Holdings, Consensus Business Group (CBG) and angel investors, will accelerate United States commercial expansion, support ongoing clinical research and product development and broaden patient access to LibAirty.

Launched in 2025, the LibAirty system deliver airway clearance therapy through a daily home treatment that Synchrony said has shown the ability to clear twice as much sputum as conventional therapies.

“This funding enables us to advance our mission of delivering meaningful clinical outcomes by bringing effective, easy-to-use airway clearance into more homes and empowering patients to manage their respiratory health,” said Anat Shani, CEO of Synchrony Medical. “Supported by our exceptional investors and new board members, we’re well positioned to scale our U.S. market presence, expand our clinical evidence base, and advance product innovation.”

In conjunction with the funding, Synchrony announced the appointment of Kevin Kotler, general partner of Broadfin Holdings, and Elad Duschak, strategic advisor to CBG for Healthcare, to the company’s board of directors.

“The LibAirty System, with its proven clinical advantage, is poised to disrupt a market with high demand and strong growth,” said Kevin Kotler, general partner of Broadfin Holdings. “We look forward to working with the team to scale nationwide and create meaningful value for both patients and shareholders.”

Synchrony said it will continue to expand its U.S. team and operations from its Jersey City headquarters. The financing includes $1 million in funding from the NJEDA through the New Jersey Innovation Evergreen Fund (NJIEF)’s co-investment with Edge Medical Ventures, further supporting the company’s growth and presence in the state.